Diphencyprone Inhibitor

Diphencyprone is a topically administered drug intended for the treatment,of alopecia areata and alopecia totalis. It acts as a local irritant, triggering a local sensitization. It triggers an immune response that opposes the action of the autoreactive cells that otherwise cause hair loss.

Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment, Exp Dermatol. 2016 Apr 8. doi: 10.1111/exd.13030. [Epub ahead of print] PubMed PMID: 27061281.
Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment,of alopecia areata. Clin Exp Dermatol. 2015 Dec 1. doi: 10.1111/ced.12776. [Epub ahead of print] PubMed PMID: 26620737.
Moncrieff M, Fadhil M, Garioch J. Topical diphencyprone for the treatment,of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience. Br J Dermatol. 2015 Nov 24. doi: 10.1111/bjd.14314. [Epub ahead of print] PubMed PMID: 26598951.
Bulock KG, Cardia JP, Pavco PA, Levis WR. Diphencyprone treatment,of Alopecia Areata: Postulated Mechanism of Action and Prospects for Therapeutic Synergy with RNA Interference. J Investig Dermatol Symp Proc. 2015 Nov;17(2):16-8. doi: 10.1038/jidsymp.2015.33. PubMed PMID: 26551938.

Small volumes of Diphencyprone, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756746 is an inhibitor targeting Diphencyprone.